ROBYN HUDSON: Open Payments
NPI 1528660552 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$760 in 41 payments from 11 companies in 2025. Trend: 2023 $380 · 2024 $758 · 2025 $760
Food & beverage: $760
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $229 |
| ABBVIE INC. | 10 | $181 |
| AstraZeneca Pharmaceuticals LP | 5 | $80 |
| Lilly USA, LLC | 3 | $52 |
| GlaxoSmithKline, LLC. | 3 | $52 |
| UCB, Inc. | 2 | $43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Exact Sciences Corporation | 1 | $18 |
Products named: Ozempic, VRAYLAR, AIRSUPRA, MOUNJARO, XIFAXAN, TRELEGY ELLIPTA, VOQUEZNA, Fintepla.
Industry payments across MS — which companies pay providers there.
